Why Is IMMUNOVANT INC (IMVT) Stock Up Today?

Immunovant shares rose 15.13% to close at $35.15. The primary driver was a positive earnings report in which the company beat consensus estimates, coupled with clinical progress in its rheumatoid arthritis program.

What Happened

Immunovant reported fiscal second quarter results with a GAAP EPS of negative $0.47, which beat the consensus estimate of negative $0.72 by $0.27. The net loss narrowed as R&D spending fell. The company also disclosed that its IMVT-1402 600mg dose met the primary endpoint in a difficult-to-treat rheumatoid arthritis trial, while the 300mg dose showed no difference from placebo. Immunovant filed an automatic mixed securities shelf prospectus with terms undisclosed.

What The Data Shows

The stock has printed seven fresh 52-week highs and one fresh 52-week low on November 9, 2026. The 52-week range stands at $21.43 to $45.42. Over the last eight sessions, the stock moved 3.8% from $29.42 to $30.53 prior to the current session. The company has a market cap of $6.3B and a beta of 0.94. It remains unprofitable with a trailing twelve-month EPS of negative $2.82. Insider activity shows nine sells totaling $923K in the last 90 days, with no buys. Recent sales include CFO Girao Tiago on October 28, 2026, CTO Stout Jay S on October 21, 2026, and COO Gloria Melanie on October 7, 2026.

What To Watch

Investors will monitor the upcoming Q2 2027 earnings call scheduled for November 9, 2026, at 8:00 AM EST. The market will also watch for further details on the mixed securities shelf offering and additional readouts from the rheumatoid arthritis program.